Efforts to develop drugs targeting CB1R have primarily focused on their roles in neuromodulation and metabolic regulation, particularly in obesity treatment, while CB2R has been explored for its ability to regulate inflammatory processes and immune-related disorders (Aso and Ferrer, 2016; Kaur et al., 2016; Vuic et al., 2022), with further potential to treat or ameliorate certain neurodegenerative disorders (Navarro et al., 2016; An et al., 2020; Bala et al., 2024). Here, CNR1 is linked to obesity disorder.